Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Eikon Therapeutics
Novartis
GlaxoSmithKline
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
San Raffaele University
VA Office of Research and Development
Radiopharm Theranostics, Ltd
Replimune Inc.
Fudan University
St. Jude Children's Research Hospital
University of Cincinnati
GlaxoSmithKline
Shanghai Zhongshan Hospital
Women's Hospital School Of Medicine Zhejiang University
UNICANCER